Insulin efsitora alfa for Adults With Type 2 Diabetes

As of August 2026, MARA’s assessment finds Insulin efsitora alfa’s reimbursement risk concentrated in clinical effectiveness and quality of life, with care pathway integration a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs safety and adverse effects: what harms arrive alongside the benefit, which payers set against the gains before funding a treatment. The strength recorded in care pathway integration carries weight because that domain asks how the drug fits into the way care is organised today; a treatment that demands new infrastructure or displaces an established pathway faces extra scrutiny.

Endocrinology

This rating sits within MARA’s Endocrinology coverage, alongside 9 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

Efsitora demonstrated noninferior HbA1c control compared to daily basal insulin in four phase 3 trials, but not superior efficacy. The trials were designed to show noninferiority, not superiority, in glycemic control.

Does the economic case hold at the expected price? — Cost effectiveness

No publicly available ICER, incremental cost, or cost-utility model was identified. NICE’s appraisal is still in development.

Is there quality-of-life evidence payers weigh? — Quality of life

Patient-reported outcomes showed favorable treatment satisfaction and burden measures, but generic HRQoL measured by EQ-5D-5L and SF-36v2 was similar to daily basal insulin.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Overall adverse-event profiles were similar to daily basal insulin. QWINT-1 showed a favorable hypoglycemia profile, but this was not consistently replicated in other trials.

Was the drug compared against what payers expect? — Comparator Selection

Trials compared efitora against appropriate daily basal insulin comparators (glargine and degludec), but not against the once-weekly insulin icodec.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trials covered a broad range of insulin-experienced populations, but representativeness is limited by trial eligibility criteria and lack of robust subgroup analyses.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

Efsitora fits into existing basal insulin treatment pathways with minor adjustments needed for weekly administration.

Are the wider system costs understood? — Resource Use and Cost Implications

No budget-impact or resource-use data were presented. The economic evidence is immature.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The evidence is based on multiple randomized, active-controlled phase 3 trials. However, the trials were open-label, which affects subjective outcomes.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

Uncertainty exists regarding long-term outcomes, real-world effectiveness, and economic value. No sensitivity analysis was available due to the lack of a public ICER.

Request the current rating

Be alerted when this rating changes:

Related Reimbursement Risk Assessments

Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.